Histotripsy demonstrated an 82.5% efficacy rate at one month when treating 60 liver tumors across 30 patients, using focused ultrasound waves to mechanically destroy cancer cells through acoustic cavitation. The non-invasive procedure achieved 95% technical success at 36 hours, with a median tumor size of 1.8 cm treated under general anesthesia. This represents a significant advancement in liver cancer treatment, offering patients an alternative to surgical resection or thermal ablation techniques. Unlike radiofrequency or microwave ablation that rely on heat, histotripsy's mechanical disruption may preserve surrounding liver architecture more effectively, potentially expanding treatment options for patients with compromised liver function or tumors in challenging locations. The study's inclusion of both primary hepatocellular carcinoma and metastases from colorectal, pancreatic, breast, and thyroid origins suggests broad applicability across cancer types. However, the single-center design and relatively small cohort limit generalizability. The technology's reliance on precise ultrasound targeting may also restrict its use in patients with significant abdominal scarring or obesity. While promising, histotripsy requires validation through larger multicenter trials and longer follow-up to establish durability compared to established liver-directed therapies.